Obinutuzumab + Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone/Prednisolone/Methylprednisolone + Vincristine
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Advanced Follicular Lymphoma
Conditions
Advanced Follicular Lymphoma
Trial Timeline
Feb 26, 2019 → Jan 25, 2023
NCT ID
NCT03817853About Obinutuzumab + Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone/Prednisolone/Methylprednisolone + Vincristine
Obinutuzumab + Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone/Prednisolone/Methylprednisolone + Vincristine is a approved stage product being developed by Roche for Advanced Follicular Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03817853. Target conditions include Advanced Follicular Lymphoma.
What happened to similar drugs?
15 of 20 similar drugs in Advanced Follicular Lymphoma were approved
Approved (15) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03817853 | Approved | Completed |
Competing Products
20 competing products in Advanced Follicular Lymphoma